like a very reasonable entry point. I bought a few last week--one of my more astute friends suggested this one to me. Maybe someone will do some last minute tax loss selling on Monday and I can get a few more cheaply. My gut says 5.50 or so by end of Jan. on a bounce--that is a very decent return from these levels. . PHIII trial seems somewhat de-risked so maybe by mid year we are much higher. Decent risk/return for a small biotech.
Welcome to the board. I've got orders in for "bottom shopping" today at 4.64 and 4.50. Today should be the last day of selling pressure moving into the new year. ESTABLISH-2 is very much de-risked and the trial has been designed with FDA input. CEO, Jeff Stein, expects better results due to the higher bioavailability of the IV formulation. If history repeats itself, we may see a similar run-up that we saw going into ESTABLISH-1. My price target is around $7 on the run-up. Trius has tapped the ATM twice... the first time for around 3 million and the second around 5 million. That would leave about 17 million left.